New endocrine therapy for patients with scirrhous type gastric cancer using LH-RH analogue (Zoladex)

为了改善顽固性胃癌患者的预后，我们研究了一种新的内分泌治疗方法——rh - rh类似物（Zoladex）。1. 抑制癌细胞系的研究。结果表明，1 × 10^<-6 bb0 -10^<-7 bb1 M Zoladex与E_2对KATO-III细胞系（雌激素受体阳性细胞）的增殖有抑制作用。另一方面，1 × 10^<-6 bb0 -10^<-7 bb1 M Zoladex与E_2对MKOI （ER阴性细胞）的增殖没有抑制作用。在携带异种移植瘤的裸鼠中，Zoladex对Kato-III细胞有抑制作用。scirrhouse型胃癌患者服用唑拉地克后血清雌激素水平降低。然而，尚不清楚Zoladex是否能减少scirrhouss型胃癌的大小。在本研究中，可以得出结论，唑拉地克斯可能是有效的治疗scirrhouss型胃癌。

In order to improving prognosis of scirrhous type gastric cancer patients, we studied new endocrine therapy using LH-RH analogue (Zoladex). 1. Studies on inhibition of cancer cell line. It was found that the proliferation of the KATO-III cell line (estrogenreceptor-positivecell) was inhibited by 1x10^<-6>-10^<-7>M Zoladex with E_2. On the other hand, the proliferation of MKOI (ER negative cell) was not inhibited by 1x10^<-6>-10^<-7>M Zoladex with E_2. In nude mouse bearing xenograft tumor, Kato-III cells were inhibited by Zoladex. In patients with scirrhous-type gastric cancer, the levels of serum estrogen decreased after administration of Zoladex. However, it was not clear that the size of scirrhous-type gastric cancer decreased by Zoladex. In the present study, it can be concluded that Zoladex might be useful for the treatment of scirrhous-type gastric cacer.